The U.S. Food and Drug Administration has given clearance for a Phase 2B clinical trial to evaluate the safety, tolerability, and efficacy of Nueraly‘s investigational therapy NLY01 in people with Alzheimer’s disease. The randomized, double-blinded, placebo-controlled trial is expected to enroll more than 500 people with mild cognitive impairment due to Alzheimer’s disease at more than 100 sites in the U.S., Canada, and Europe. Results from the trial are expected by the end of 2023.…
You must be logged in to read/download the full post.
The post FDA Clears Neuraly to Begin Phase 2 Trial of NLY01 in Alzheimer’s Patients appeared first on BioNewsFeeds.